Appendix 4: Table of methodology and the key results for the diabetic population (Risk Ratio) in the 7 landmark randomised control trials included in the analysis

STUDY	Patient Population	Treatment 1	Treatment 2	Primary Outcome	Secondary Outcome	Follow Up	Final diagnosis	Length of DAPT	Coronary Angio-graphy	PCI or Revascularised (PCI & CABG)	No of DM Patients (% of total pop)	Risk Ratio	CI 95%
CAPRIE*	Recent athero-thrombotic symptoms (CVA/MI/ PVD)	Clopidogrel 75mg OD	Aspirin 325mg OD	Composite CV death/ MI/CVA	Any death Bleeding Amputation	3 years (mean 1.9)	MI 32.8% (other PVD/ stroke)	1-3 years mono-therapy	-	-	3866 (20%)	0.88	(0.77-1.02)
CURE*	NSTEMI/ UA patients within 24hours	Clopidogrel 75mg OD	Placebo	Composite CV death/ MI/CVA	Composite CV death/ MI/CVA/ ischaemia Bleeding, Heart failure Revascular-isation	12 months	UA 74.9% NSTEMI 25.1%	3-12 months	-	PCI 21.2% CABG 15.2%	2840 (23%)	0.85	(0.72-1.01)
PCI-CLARITY*	STEMI patients receiving fibrinolysis due to undergo PCI at day 2-8	Clopidogrel 300mg at time of fibrinolysis then 75mg OD	Placebo at time of fibrinolysis	Composite CV death/ MI/CVA from time of PCI	Before PCI MI/CVA Bleeding	30 days	STEMI 100%	30 days	93.8 %	PCI 53.4 % *Data of non PCI patients excluded in final outcomes*	282 (15%)	0.60	(0.26-1.36)
CURRENT-OASIS*	ACS referred for PCI	Clopidogrel loading 600mg Day2-7	Clopidogrel loading 300mg then 75mg OD	Composite CV death/ MI/CVA	CV death Any death MI, CVA Recurrent	30 days	NSTEMI/UA 70.1% STEMI 29.2%	30 days	99.0 %	PCI 68.8 % *Data of non PCI patients*	5880 (23%)	0.85	(0.69-1.05)

Appendix 4: Table of methodology and the key results for the diabetic population (Risk Ratio) in the 7 landmark randomised control trials included in the analysis

		150mg OD then 75mg OD either low or high dose aspirin	with either low or high dose aspirin		ischaemia Stent thrombosis Bleeding					*excluded in final outcomes*			
TRITON – TIMI 38	ACS with scheduled PCI	Prasugrel 10mg OD	Clopidogrel 75mg OD	Composite CV death/ MI/CVA	Bleeding Ischaemia Revascular-isation Stent thrombosis	15 months	NSTEMI/UA 79% STEMI 21%	12 months	100% Inclusion criteria	PCI 99.0 % CABG 1.0%	3146 (23%)	0.72	(0.60-0.85)
TRILOGY*	NSTEMI /UA patients <75 years old without revasc-ularisation	Prasugrel 10mg OD	Clopidogrel 75mg OD	Composite CV death/ MI/CVA	Bleeding Ischaemia Stent thrombosis	30 months (median 17.1)	UA 32.5% NSTEMI 67.5%	6-30 months	41 % Prior to random-isation	PCI 6.0% CABG 2.3%	2811 (39%)	0.87	(0.76-1.00)
PLATO	ACS patients (both PCI and medically managed)	Ticagrelor 90mg BD	Clopidogrel 75mg OD	Composite CV death/ MI/CVA	Bleeding Any death Stent thrombosis	12 months	STEMI 28.7% NSTEMI 47.6% UA 20.9 % Other 2.8 %	12 months	77.4 %	PCI 58.0 % CABG 13.2%	4662 (25%)	0.89	(0.77-1.02)

No trials included patients on triple therapy (dual antiplatelet and anticoagulant) as exclusion criteria

* Percentage for diagnosis/angiography/revascularisation from general study population as specific diabetic patient data not available